Failure Rate and “Professional Subjects” in Clinical Trials of Major Depressive Disorder
J Clin Psychiatry 2011;72(9):1284 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Letter to the Editor
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
We commend Khin et al on a thorough and comprehensive article detailing the declining treatment effect and high failure rate in major depressive disorder (MDD) trials. We wish to highlight an area that we believe is a major factor in the increasing failure rate of studies: the choice of subjects. Specifically, we believe that failure rates are rising due to the increase in “professional subjects,” who go from site to site, learning inclusion and exclusion criteria and collecting stipends.